about
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerChemokines as therapeutic targets in renal cell carcinomaCXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer.Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC.Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines.Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.The FEN1 E359K germline mutation disrupts the FEN1-WRN interaction and FEN1 GEN activity, causing aneuploidy-associated cancers.A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.Myeloid clusters are associated with a pro-metastatic environment and poor prognosis in smoking-related early stage non-small cell lung cancerAnticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasisAntiangiogenic and antimetastatic activity of JAK inhibitor AZD1480.Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).Akt inhibitors in clinical development for the treatment of cancer.Targeted therapies for non-small cell lung cancer: an evolving landscape.Serum LAMC2 enhances the prognostic value of a multi-parametric panel in non-small cell lung cancer.Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.Interdisciplinary Palliative Care for Patients With Lung Cancer.Long-Term Effect of an Interdisciplinary Supportive Care Intervention for Lung Cancer Survivors After Surgical Procedures.The potential and rationale for COX-2 inhibitors in lung cancer.Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.Inflammation and lung carcinogenesis: applying findings in prevention and treatment.Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance.Non-small cell lung cancer in the elderly: defining treatment options.(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.The role of targeting mammalian target of rapamycin in lung cancer.Management of non-small-cell lung cancer in the older adult.Phosphatidylinositol-3-kinase pathway.The impact of lung cancer surgery on quality of life trajectories in patients and family caregivers.Preparing Cancer Patients and Family Caregivers for Lung Surgery: Development of a Multimedia Self-Management Intervention.Future of ALK inhibition in non-small-cell lung cancer.Predictors of finding benefit after lung cancer diagnosis.Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium.A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner.
P50
Q29620902-3C011FAF-301A-4B6F-BFA2-48AAC79D1C36Q30435873-99E62A0E-D2CD-490D-B614-ABDCA8E7660BQ30439235-1D52656C-EE59-4A19-AE93-5EDB84BFB5C6Q33159653-607C45EA-E1B8-4FFA-AABC-B683C46D6686Q33396761-E1562C16-6D9B-4E3C-BBFE-03C4643ADD1EQ33610890-EB1B85E7-760D-42FD-8CFF-156CA0791A73Q33628868-7866FF72-B929-4F20-97CE-D525D94D0513Q34089521-C3810161-4D92-414A-847A-188C44300F0DQ34161115-4CFC4784-6572-47ED-9EFB-BA96BAEE139FQ34180815-57B341C4-B441-4700-9701-1E92718B2845Q34473451-84D0C2F2-9905-4A5D-A49C-E14E4D15A0B9Q34687059-419130C8-39A2-4C65-BD13-29E706FCF05BQ34746658-B61C028A-AC12-4FF9-81EF-397D5E5894FAQ35050195-3FEA9EF6-A0C8-4427-8F07-9B27747A009AQ35131138-6D0E5CEA-405C-4A4E-9B84-C0E55025F1BEQ35501550-8FF5FA26-4573-40A6-9D04-6CE52780DC3AQ35561508-0E3A4B04-7E21-4AFA-AB8E-34406AB86DE5Q35628576-6BA2F907-76B8-4EE3-B6EE-E12CC8A4A322Q35628597-810423D1-44C1-485F-B486-09EFC403D527Q35909576-9822F66C-EBEF-43B9-81BB-4B3484DCA65BQ36117718-E68D0619-81BD-469D-92B6-3EE46ABB52EEQ36338485-430FEAB7-9B04-430D-9428-0B565DA82080Q36480005-9F03CCAD-C361-45E6-8407-DEBE53858605Q36482948-81670266-56E0-4A8D-8EEA-C4A8E9FFC947Q36716682-5BFEC964-5D66-468C-AA8E-FC8629ECC790Q36892544-8AD361CD-9BA6-4402-90A7-3C17C68088BCQ36974700-C6DB715F-3EAE-45D0-9EC0-05354F38361CQ37095803-4DD5E9B1-4899-4176-BC10-29A3AA7EDE07Q37240128-31993065-6A93-4D5C-828E-DF8D962A9654Q37253248-D49B9E2B-EA54-48B0-BED2-60E87F8D44D4Q37346520-24F91151-FB85-49CC-AEA1-A3C6758F3A83Q37835956-9855605F-907D-4058-BFFA-570A8403B212Q38060510-BDBEC7DF-BF88-4730-9251-3E2D560F2760Q38385582-1F6719CA-CD6A-4C18-80A6-CCF3B70B5F34Q38829693-F0424E39-1038-4B5E-8873-E77755D47D2EQ39140325-625E5373-17D0-4F40-8511-09F7694F2518Q39791374-3CFEBE2C-F45D-4871-95AA-CF357DD921D0Q39968486-5BF1C00B-30B3-489D-9BF7-476C0D87DFC3Q40320009-9E50D8D6-943E-47A3-B04A-6337A281207AQ40396797-1ED361C4-62F6-4251-83EF-F605DCB48AE1
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Karen L. Reckamp
@ast
Karen L. Reckamp
@en
Karen L. Reckamp
@es
Karen L. Reckamp
@nl
Karen L. Reckamp
@sl
type
label
Karen L. Reckamp
@ast
Karen L. Reckamp
@en
Karen L. Reckamp
@es
Karen L. Reckamp
@nl
Karen L. Reckamp
@sl
altLabel
Karen L. Riedl
@en
prefLabel
Karen L. Reckamp
@ast
Karen L. Reckamp
@en
Karen L. Reckamp
@es
Karen L. Reckamp
@nl
Karen L. Reckamp
@sl
P106
P1153
8915312400
P21
P31
P496
0000-0002-9213-0325